Regeneron Pharmaceuticals, Inc. (REGN) Stock Score, Valuation & Financial Research
Regeneron Pharmaceuticals, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 55/100.
Quick answer for REGN
Regeneron Pharmaceuticals, Inc. currently has a Wall Street Score of 55/100. The stored market price is $781.49. Its financial score is 43/100. Its valuation score is 30/100. These figures are a research snapshot, not a buy or sell recommendation.
What Regeneron Pharmaceuticals, Inc. does
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV
REGN financial snapshot
- Wall Street Score:
- 55/100
- Current price:
- $781.49
- Market capitalization:
- $80.51B
- Revenue:
- $14.92B
- Net income:
- $4.42B
- Free cash flow:
- $4.08B
- Cash:
- $2.96B
- Total debt:
- $2.71B
- EPS:
- 43.07
- P/E ratio:
- 18.1x
- Financial score:
- 43/100
- Valuation score:
- 30/100
- Revenue score:
- 28/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $4.08B, showing positive cash generation.
- The balance sheet shows $2.96B of cash versus $2.71B of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 30/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 43/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research REGN
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.